Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Cash from Investing Activities: 2020-2024

Historic Cash from Investing Activities for Immuneering (IMRX) over the last 5 years, with Dec 2024 value amounting to $26.4 million.

  • Immuneering's Cash from Investing Activities rose 75.26% to $5.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $26.4 million, marking a year-over-year increase of 262.30%. This contributed to the annual value of $26.4 million for FY2024, which is 262.30% up from last year.
  • According to the latest figures from FY2024, Immuneering's Cash from Investing Activities is $26.4 million, which was up 262.30% from $7.3 million recorded in FY2023.
  • Immuneering's 5-year Cash from Investing Activities high stood at $41.8 million for FY2022, and its period low was -$75.6 million during FY2021.
  • Over the past 3 years, Immuneering's median Cash from Investing Activities value was $26.4 million (recorded in 2024), while the average stood at $25.2 million.
  • In the last 5 years, Immuneering's Cash from Investing Activities plummeted by 141,463.17% in 2021 and then soared by 262.30% in 2024.
  • Immuneering's Cash from Investing Activities (Yearly) stood at -$53,415 in 2020, then slumped by 141,463.17% to -$75.6 million in 2021, then skyrocketed by 155.32% to $41.8 million in 2022, then plummeted by 82.56% to $7.3 million in 2023, then surged by 262.30% to $26.4 million in 2024.